Three of Takeda's diabetes therapies get positive opinion from EMA unit
Japan’s largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for three new type 2 diabetes therapies.
Vipidia (alogliptin) and fixed-dose combinations Vipdomet (alogliptin-metformin) and Incresync (alogliptin-pioglitazone) are indicated for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies.
Trevor Smith, head of commercial operations, Europe & Canada, Takeda Pharmaceuticals, said: “The number of people at risk from complications associated with type 2 diabetes continues to rise across Europe as many still fail to reach treatment goals. This positive opinion marks an important milestone in Takeda’s ongoing commitment in working to advance patient care and helping to meet the individual needs of this growing patient population.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze